For oral contraceptive users, coagulation monitoring (factor VIII, vWF, APC resistance) may identify high‐risk individuals, while obesity management—focused on reducing inflammatory states and improving coagulation factor profiles—represents a key preventive strategy (Zuurbier et al. The gene discussed is VWF; the disease is obesity disorder.